SG10202007103TA - Aadc polynucleotides for the treatment of parkinson's disease - Google Patents

Aadc polynucleotides for the treatment of parkinson's disease

Info

Publication number
SG10202007103TA
SG10202007103TA SG10202007103TA SG10202007103TA SG10202007103TA SG 10202007103T A SG10202007103T A SG 10202007103TA SG 10202007103T A SG10202007103T A SG 10202007103TA SG 10202007103T A SG10202007103T A SG 10202007103TA SG 10202007103T A SG10202007103T A SG 10202007103TA
Authority
SG
Singapore
Prior art keywords
parkinson
disease
treatment
aadc polynucleotides
aadc
Prior art date
Application number
SG10202007103TA
Inventor
Robert Kotin
Adrian Philip Kells
Bernard Ravina
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of SG10202007103TA publication Critical patent/SG10202007103TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10202007103TA 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease SG10202007103TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462075298P 2014-11-05 2014-11-05
US201562155692P 2015-05-01 2015-05-01
US201562199578P 2015-07-31 2015-07-31
US201562243537P 2015-10-19 2015-10-19

Publications (1)

Publication Number Publication Date
SG10202007103TA true SG10202007103TA (en) 2020-09-29

Family

ID=55910029

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703148TA SG11201703148TA (en) 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease
SG10202007103TA SG10202007103TA (en) 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201703148TA SG11201703148TA (en) 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease

Country Status (14)

Country Link
US (6) US10335466B2 (en)
EP (1) EP3215191A4 (en)
JP (4) JP6401871B2 (en)
KR (1) KR20170096998A (en)
CN (2) CN112553229A (en)
AU (2) AU2015343037B2 (en)
BR (1) BR112017009497A2 (en)
CA (1) CA2966620A1 (en)
HK (1) HK1243922A1 (en)
IL (2) IL251787B (en)
MX (1) MX2017005834A (en)
RU (2) RU2716991C2 (en)
SG (2) SG11201703148TA (en)
WO (1) WO2016073693A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170096998A (en) 2014-11-05 2017-08-25 보이저 테라퓨틱스, 인크. Aadc polynucleotides for the treatment of parkinson's disease
CN112410338A (en) 2014-11-14 2021-02-26 沃雅戈治疗公司 Regulatory polynucleotides
EP3245221A4 (en) * 2015-01-16 2018-06-13 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
SG11201809643UA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
AU2017321488B2 (en) 2016-08-30 2022-10-20 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3519431A1 (en) 2016-09-28 2019-08-07 Cohbar Inc. Therapeutic mots-c related peptides
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
SG11201907653QA (en) * 2017-03-17 2019-09-27 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
CA3061368A1 (en) * 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
JOP20190269A1 (en) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11807849B2 (en) * 2017-10-03 2023-11-07 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
WO2019210137A1 (en) * 2018-04-27 2019-10-31 Voyager Therapeutics, Inc. Methods for measuring the potency of aadc viral vectors
US20210198691A1 (en) * 2018-05-15 2021-07-01 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3793686A1 (en) * 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
US20210301305A1 (en) 2018-06-13 2021-09-30 Voyager Therapeutics, Inc. Engineered untranslated regions (utr) for aav production
CN114908099A (en) * 2018-06-28 2022-08-16 北京锦篮基因科技有限公司 Recombinant adeno-associated virus carrying SMN1 gene expression cassette and application thereof
SG11202100704PA (en) 2018-07-24 2021-02-25 Voyager Therapeutics Inc Systems and methods for producing gene therapy formulations
US20210348242A1 (en) 2018-10-04 2021-11-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
CN113166731A (en) 2018-10-05 2021-07-23 沃雅戈治疗公司 Engineered nucleic acid constructs encoding AAV production proteins
AU2019360937A1 (en) 2018-10-15 2021-05-20 Voyager Therapeutics, Inc. Expression vectors for large-scale production of rAAV in the baculovirus/Sf9 system
WO2020150556A1 (en) 2019-01-18 2020-07-23 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
JP2022518814A (en) 2019-01-28 2022-03-16 コーバー、インコーポレイテッド Therapeutic peptide
WO2020160508A1 (en) 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
EP3962536A1 (en) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
TW202122582A (en) 2019-08-26 2021-06-16 美商航海家醫療公司 Controlled expression of viral proteins
CN115135347A (en) * 2019-12-12 2022-09-30 梅里特斯英国第二有限公司 Methods of treating Parkinson's disease
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP3982378A1 (en) 2020-10-09 2022-04-13 Koninklijke Philips N.V. Cryogen-free superconducting magnet system
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
BR112023016873A2 (en) * 2021-03-12 2023-10-03 Kolon Life Science Inc COMPOSITION TO PREVENT OR TREAT DEGENERATIVE BRAIN DISEASES
WO2022212273A1 (en) * 2021-03-29 2022-10-06 Sanford Health Methods and compositions for treating lysosomal storage disorders
WO2023279078A1 (en) * 2021-07-01 2023-01-05 Northwestern University Enhanced expression of an aromatic amino acid decarboxylase (aadc) in the substantia nigra for the treatment of parkinson's disease
WO2023056399A1 (en) 2021-10-02 2023-04-06 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
WO2023093905A1 (en) * 2021-11-29 2023-06-01 上海瑞宏迪医药有限公司 Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
WO2023202637A1 (en) * 2022-04-19 2023-10-26 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating neurodegenerative disorders
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins

Family Cites Families (457)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2640638B1 (en) 1988-12-20 1991-02-15 Commissariat Energie Atomique BIOREACTOR AND DEVICE FOR THE CULTURE OF ANIMAL CELLS
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
GB9027917D0 (en) * 1990-12-21 1991-02-13 Ici Plc Expression systems
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US7026468B2 (en) 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
AU722375B2 (en) 1996-09-06 2000-08-03 Trustees Of The University Of Pennsylvania, The Methods using cre-lox for production of recombinant adeno-associated viruses
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
AU723497C (en) 1996-09-06 2001-10-11 Trustees Of The University Of Pennsylvania, The Method for recombinant adeno-associated virus-directed gene therapy
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5866552A (en) 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
US20020037867A1 (en) 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
CA2265460A1 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ES2383640T3 (en) 1996-11-20 2012-06-25 Crucell Holland B.V. Adenovirus compositions that can be obtained by an improved production and purification method
AU741605B2 (en) 1996-12-18 2001-12-06 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6710036B2 (en) 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
EP1015619A1 (en) 1997-09-19 2000-07-05 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
AU9774998A (en) 1997-09-19 1999-04-12 Trustees Of The University Of Pennsylvania, The Method for gene transfer using bcl2 and compositions useful therein
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
IT1297074B1 (en) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio HORMONE-DEPENDENT FORMS OF THE REP PROTEIN OF THE ADENUS ASSOCIATED VIRUS (AAV-2), DNA SEQUENCES CODING FOR THEM, VECTORS THAT
AU759573B2 (en) 1997-12-23 2003-04-17 Crucell Holland B.V. Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal DNA of target cells
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
AU2882899A (en) 1998-02-26 1999-09-15 Trustees Of The University Of Pennsylvania, The Stable protection from dystrophic sarcolemmal degeneration and restoration of the sarcoglycan complex
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6521426B1 (en) 1998-04-08 2003-02-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus
FR2778413B1 (en) 1998-05-07 2000-08-04 Immunotech Sa NOVEL REAGENTS AND METHOD FOR LYSIS OF ERYTHROCYTES
EP1078096A1 (en) 1998-05-11 2001-02-28 Ariad Gene Therapeutics, Inc. Multiviral compositions and uses thereof
EP1849872A1 (en) 1998-05-20 2007-10-31 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
ES2326893T3 (en) 1998-05-27 2009-10-21 Genzyme Corporation AAV VECTORS FOR THE MANUFACTURE OF MEDICINES FOR ADMINISTRATION POTENTIATED BY CONVECTION.
EP1621626B1 (en) 1998-05-27 2009-07-08 Genzyme Corporation AAV Vectors for the manufacture of medicaments for convection enhanced delivery
EP1082445A2 (en) 1998-05-27 2001-03-14 Cell Genesys, Inc. Adeno-associated viral vector-mediated expression of factor viii activity
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
CA2329060C (en) 1998-05-28 2011-09-13 John A. Chiorini Aav5 vector and uses thereof
GB2338236B (en) 1998-06-13 2003-04-09 Aea Technology Plc Microbiological cell processing
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
WO2000022152A1 (en) 1998-10-13 2000-04-20 Avigen, Inc. Compositions and methods for producing recombinant adeno-associated virus
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
CA2348838A1 (en) 1998-10-27 2000-05-04 Crucell Holland B.V. Improved aav vector production
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
DE19905501B4 (en) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament
US6509150B1 (en) 1999-03-05 2003-01-21 Universite De Nantes Compositions and methods for recombinant Adeno-Associated Virus production
JP4693244B2 (en) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for helperless production of recombinant adeno-associated virus
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU4807400A (en) 1999-04-30 2000-11-17 University Of Florida Adeno-associated virus-delivered ribozyme compositions and methods of use
WO2000075353A1 (en) 1999-06-02 2000-12-14 Trustees Of The University Of Pennsylvania Compositions and methods useful for production of recombinant viruses which require helper viruses
WO2001014539A2 (en) 1999-08-20 2001-03-01 Johns Hopkins University School Of Medicine Methods and compositions for the construction and use of fusion libraries
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
JP2003523320A (en) 1999-09-29 2003-08-05 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Methods for rapid PEG modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
CA2386546A1 (en) 1999-10-07 2001-04-12 University Of Iowa Research Foundation Adeno-associated viruses and uses thereof
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
AU3642601A (en) 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
WO2001036603A2 (en) 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
WO2001042444A2 (en) 1999-12-10 2001-06-14 Ariad Gene Therapeutics, Inc. Methods for expression of genes in primates
US20020045264A1 (en) 2000-03-14 2002-04-18 During Matthew J. Production of chimeric capsid vectors
US7638120B2 (en) 2000-03-14 2009-12-29 Thomas Jefferson University High transgene expression of a pseudotyped adeno-associated virus type
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
GB0009887D0 (en) 2000-04-20 2000-06-07 Btg Int Ltd Cytotoxic agents
US20030013189A1 (en) 2000-04-28 2003-01-16 Wilson James M. Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
JP2004514407A (en) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア AAV5 capsid pseudotyped in heterologous capsid and recombinant AAV vector comprising AAV5 vector
WO2001083797A2 (en) 2000-04-28 2001-11-08 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
EP1299126B1 (en) 2000-05-23 2004-10-27 Neurologix, Inc. Glutamic acid decarboxylase (gad) delivery system for treating neurodegenerative diseases
WO2001096587A2 (en) 2000-06-13 2001-12-20 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
US7045299B2 (en) 2000-07-18 2006-05-16 Takeda Pharmaceutical Company Limited Physiologically active peptide and use thereof
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6329181B1 (en) 2000-08-07 2001-12-11 Neurologix, Inc. Helper functions for recombinant vector production
AU2001294096A1 (en) 2000-08-17 2002-02-25 Uichi Ikeda Adeno-associated virus-mediated delivery of angiogenic factors
DE10066104A1 (en) 2000-09-08 2003-01-09 Medigene Ag Host cells for packaging recombinant adeno-associated virus (rAAV), process for their preparation and their use
FR2813891B1 (en) 2000-09-14 2005-01-14 Immunotech Sa MULTIFUNCTIONAL REAGENT FOR ERYTHROCYTES INVOLVING CARBAMATES AND APPLICATIONS
GB0024550D0 (en) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
JP2002153278A (en) 2000-11-22 2002-05-28 Hisamitsu Pharmaceut Co Inc Cell for producing virus vector, method for producing the virus vector and method for producing virus vector using the cell
WO2002070719A2 (en) 2001-01-19 2002-09-12 Trustees Of The University Of Pennsylvania Regulatable gene expression system
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
JP2004532822A (en) 2001-03-14 2004-10-28 アビジェン， インコーポレイテッド Recombinant adeno-associated virus-mediated gene transfer by retrograde virion infection.
US6841357B1 (en) 2001-03-30 2005-01-11 Stratagene California Method and kits for titering adeno-associated virus vectors
US7182944B2 (en) 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
US20030096264A1 (en) 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
CA2450470C (en) 2001-06-22 2012-08-28 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
EP1279740A1 (en) 2001-07-26 2003-01-29 Vrije Universiteit Brussel Recombinant vector derived from adeno-associated virus for gene therapy
US7319002B2 (en) 2001-08-08 2008-01-15 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
US20030092161A1 (en) 2001-09-19 2003-05-15 The Trustees Of The University Of Pennsylvania Compositions and methods for production of recombinant viruses, and uses therefor
WO2003042361A2 (en) 2001-11-09 2003-05-22 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CA2406745C (en) 2001-11-13 2006-01-10 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
HU230364B1 (en) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adeniovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2003049764A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
FI3517134T3 (en) 2001-12-17 2024-04-03 Univ Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same and uses therefor
EP3339430A1 (en) 2001-12-17 2018-06-27 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses thereof
CA2469658A1 (en) 2001-12-19 2003-07-03 Lijun Wang Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
JP2005538929A (en) 2002-01-16 2005-12-22 ダイナル バイオテック エイエスエイ Methods for isolating nucleic acids and proteins from a single sample
DK1504108T3 (en) 2002-02-01 2013-06-10 Oxford Biomedica Ltd lentiviral vector
GB0208390D0 (en) 2002-04-11 2002-05-22 Univ London Adeno-associated virus producer system
US20030198620A1 (en) 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
ATE348153T1 (en) 2002-04-29 2007-01-15 Univ Pennsylvania METHOD FOR DIRECT OBTAINING AND AMPLIFICATION OF INTEGRATED VIRUSES FROM CELLULAR TISSUE DNA
AU2003229159B2 (en) 2002-04-30 2008-02-21 Oncolytics Biotech Inc. Improved viral purification methods
NZ561656A (en) 2002-05-01 2009-03-31 Univ Florida Improved rAAV expression systems for genetic modification of specific capsid proteins
AU2003229060A1 (en) 2002-05-14 2003-12-02 Merck And Co., Inc. Methods of adenovirus purification
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
US7169612B2 (en) 2002-11-11 2007-01-30 Sanofi-Aventis Deutschland Gmbh Use of EDG2 receptor in an animal model of heart failure
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
US20070172460A1 (en) 2003-03-19 2007-07-26 Jurgen Kleinschmidt Random peptide library displayed on aav vectors
WO2004108922A2 (en) 2003-04-25 2004-12-16 The Trustees Of The University Of Pennsylvania Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver
WO2005017101A2 (en) 2003-05-19 2005-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Avian adenoassociated virus (aaav) and uses thereof
PT2277996E (en) 2003-05-21 2014-12-16 Genzyme Corp Methods for producing preparations of recombinant aav virions substantially free of empty capsids
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
JP4888876B2 (en) 2003-06-13 2012-02-29 田平 武 Recombinant adeno-associated virus vector for the treatment of Alzheimer's disease
EP2657248B1 (en) 2003-06-19 2017-03-22 Genzyme Corporation AAV virions with decreased immunoreactivity and uses therefor
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
ES2478625T3 (en) 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Method of generating chimeric adenoviruses and uses of such chimeric adenoviruses
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
ES2391975T3 (en) 2003-07-25 2012-12-03 Genvec, Inc. Adenoviral vector based vaccines
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2005030292A2 (en) 2003-09-26 2005-04-07 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
EP3211085B1 (en) 2003-09-30 2021-03-31 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
CN1897977A (en) * 2003-10-20 2007-01-17 Ns基因公司 In vivo gene therapy of parkinson's disease
EP1742668B1 (en) 2004-04-28 2011-02-09 The Trustees of The University of Pennsylvania Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
WO2005116224A2 (en) * 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
ES2647477T3 (en) 2004-06-01 2017-12-21 Genzyme Corporation Compositions and methods to prevent aggregation of the AAV vector
PL1807009T3 (en) 2004-10-05 2015-06-30 Genzyme Corp Stepped cannula
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN1286981C (en) 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 Combination adeno-associated virus of expression human CYP2J2 antigene and its preparation method
CN101213305A (en) 2004-12-09 2008-07-02 建新公司 Regulated expression of transgenes in the central nervous system of mammals
US8614101B2 (en) 2008-05-20 2013-12-24 Rapid Pathogen Screening, Inc. In situ lysis of cells in lateral flow immunoassays
US7625570B1 (en) 2005-03-10 2009-12-01 The Regents Of The University Of California Methods for purifying adeno-associated virus
WO2006102072A2 (en) 2005-03-23 2006-09-28 The Trustees Of The University Of Pennsylvania Use of a pa131 polypeptide in treatment of atherosclerosis
EP2357010B1 (en) 2005-04-07 2013-06-12 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
AU2006243776A1 (en) 2005-05-02 2006-11-09 Genzyme Corporation Gene therapy for neurometabolic disorders
SI3611266T1 (en) 2005-08-23 2023-02-28 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
AU2006283189B2 (en) 2005-08-23 2013-01-31 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
EP1857552A1 (en) 2006-05-20 2007-11-21 Cargill Incorporated Thermostable xylose isomerase enzyme
PL1945779T3 (en) 2005-10-20 2013-08-30 Uniqure Ip Bv Improved aav vectors produced in insect cells
WO2008016391A2 (en) 2006-01-31 2008-02-07 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
ES2618787T5 (en) 2006-04-25 2022-10-21 Univ California Administration of growth factors for the treatment of CNS disorders
ES2400235T3 (en) 2006-04-28 2013-04-08 The Trustees Of The University Of Pennsylvania AAV scalable production method
JP2009535339A (en) 2006-04-28 2009-10-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Modified AAV vectors with reduced capsid immunogenicity and uses thereof
PL2012822T3 (en) 2006-04-28 2010-06-30 Univ Pennsylvania Modified adenovirus hexon protein and uses thereof
WO2007130519A2 (en) 2006-05-02 2007-11-15 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Viral nucleic acid microarray and method of use
WO2007139982A2 (en) 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
DK2687223T3 (en) 2006-05-30 2017-10-23 Mayo Foundation Detection and treatment of dementia
LT2489733T (en) 2006-06-07 2019-05-27 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
ES2535877T3 (en) 2006-06-19 2015-05-18 Asklepios Biopharmaceutical, Inc. Modified Factor VIII and Factor IX genes and vectors for gene therapy
KR101589259B1 (en) 2006-06-21 2016-02-01 유니큐어 아이피 비.브이. -78 vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
EP2520168B1 (en) 2006-07-21 2014-03-19 California Institute of Technology Targeted gene delivery for dendritic cell vaccination
CN101522903B (en) 2006-08-24 2013-07-31 威洛克有限公司 Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
EP2097095B1 (en) 2006-11-29 2016-01-27 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
EA017403B1 (en) 2007-02-02 2012-12-28 Байоджен Айдек Эмэй Инк. Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
US9611302B2 (en) 2007-04-09 2017-04-04 University Of Florida Research Foundation, Inc. High-transduction-efficiency RAAV vectors, compositions, and methods of use
EP2623605B1 (en) 2007-04-09 2018-11-28 University of Florida Research Foundation, Inc. RAAV vector compositions having tyrosine-modified capsid proteins and methods for use
WO2008128251A1 (en) 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
ES2602610T3 (en) 2007-05-31 2017-02-21 Medigene Ag Mutated structural protein of a parvovirus
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
WO2008154198A1 (en) 2007-06-06 2008-12-18 Genzyme Corporation Gene therapy for lysosomal storage diseases
ATE535607T1 (en) 2007-06-29 2011-12-15 Hoffmann La Roche PROMOTER
EP2176283B1 (en) 2007-07-14 2016-11-02 University of Iowa Research Foundation Methods and compositions for treating brain diseases
MX2010000944A (en) 2007-07-26 2010-08-31 Amsterdam Molecular Therapeutics Bv Baculoviral vectors comprising repeated coding sequences with differential codon biases.
EP2198016B1 (en) 2007-09-04 2015-05-27 Her Majesty The Queen In Right of Canada as represented by The Minister of Health Porcine adeno-associated viruses
WO2009038462A1 (en) 2007-09-19 2009-03-26 Amsterdam Molecular Therapeutics B.V. Use of aav replication machinery for improved protein production
WO2009051421A2 (en) 2007-10-18 2009-04-23 Lg Electronics Inc. Method and system for transmitting and receiving signals
CA2704786C (en) 2007-11-02 2019-04-09 Cornell University Materials and methods for gene mediated therapy of psychiatric disorders
KR101662571B1 (en) 2007-11-28 2016-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Simian subfamily b adenoviruses sadv-28,27,-29,-32,-33, and -35 and uses thereof
MX2010005860A (en) 2007-11-28 2010-06-22 Univ Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof.
PL2220241T3 (en) 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenovirus comprising a Simian E Adenovirus SAdV-39 capsid hexon protein and uses thereof
US8133488B2 (en) 2008-01-18 2012-03-13 Genentech, Inc. Methods and compositions for targeting polyubiquitin
AU2009209408B2 (en) 2008-01-29 2015-06-11 Beacon Therapeutics Limited Recombinant virus production using mammalian cells in suspension
ES2929031T3 (en) 2008-02-19 2022-11-24 Uniqure Ip Bv Optimization of parvoviral rep and cap protein expression in insect cells
WO2009136977A2 (en) 2008-03-04 2009-11-12 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
WO2009120978A2 (en) 2008-03-27 2009-10-01 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of bdnf and compositions therfor
WO2009134681A2 (en) 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Aav7 viral vectors for targeted delivery of rpe cells
WO2009137006A2 (en) 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
CA2762118A1 (en) 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2009154452A1 (en) 2008-06-17 2009-12-23 Amsterdam Molecular Therapeutics B.V. Parvoviral capsid with incorporated Gly-Ala repeat region
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
CN102227500B (en) 2008-09-29 2013-05-29 阿姆斯特丹分子治疗(Amt)有限公司 Porphobilinogen deaminase gene therapy
JP5809978B2 (en) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Simian adenovirus SAdV-43, -45, -46, -47, -48, -49 and -50 and their uses
JP2012508591A (en) 2008-11-14 2012-04-12 ライフ テクノロジーズ コーポレーション Compositions and methods for manipulating cells
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
BRPI1013364A2 (en) 2009-03-04 2016-03-29 Deutsches Krebsforsch assembly activating protein (aap) and its use for the manufacture of parvovirus particles consisting essentially of vp3.
CN102448501A (en) 2009-03-27 2012-05-09 西马生物医学计划公司 Methods and compositions for the treatment of cirrhosis and liver fibrosis
ES2724122T3 (en) 2009-04-30 2019-09-06 Univ Pennsylvania Compositions for directing conductive airway cells comprising adeno-associated virus constructs
CA2760524C (en) 2009-05-01 2017-09-12 Redbiotec Ag Recombinant virus-like particles encoded by multi-gene vector
HUE039345T2 (en) 2009-05-02 2018-12-28 Genzyme Corp Gene therapy for neurodegenerative disorders
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
EP2435575A2 (en) 2009-05-28 2012-04-04 Deutsches Krebsforschungszentrum Modified aav capsid polypeptides
EP2435559A1 (en) 2009-05-29 2012-04-04 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
PL3067417T3 (en) 2009-06-16 2019-02-28 Genzyme Corporation Improved methods for purification of recombinant aav vectors
EP2451823A4 (en) 2009-07-06 2013-07-03 Alnylam Pharmaceuticals Inc Compositions and methods for enhancing production of a biological product
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
WO2011038187A1 (en) 2009-09-25 2011-03-31 The Trustees Of The University Of Pennsylvania Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
KR20120089743A (en) 2009-11-09 2012-08-13 제네포드 테라퓨틱스 에이비 Novel viral vector construct for neuron specific optimized continuous dopa synthesis in vivo
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
WO2011091419A2 (en) 2010-01-25 2011-07-28 New York Universiy Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
JP6141021B2 (en) 2010-02-05 2017-06-07 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Compositions and methods for enhancing parvovirus transduction
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
EP2550021A2 (en) 2010-03-22 2013-01-30 Association Institut de Myologie Methods of increasing efficiency of vector penetration of target tissue
BR112012024934A2 (en) 2010-03-29 2016-12-06 Univ Pennsylvania pharmacologically induced transgene ablation systems
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
US9272053B2 (en) 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
EP2826860B1 (en) * 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
US9546369B2 (en) 2010-04-23 2017-01-17 University Of Massachusetts Multicistronic expression constructs
US9839696B2 (en) 2010-04-30 2017-12-12 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
CA2805170C (en) * 2010-07-12 2021-09-21 Fatima Bosch Tubert Gene therapy composition for use in diabetes treatment
US8808684B2 (en) 2010-09-10 2014-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
EP2612909B1 (en) 2010-10-05 2015-02-25 Takara Bio, Inc. Method for producing virus vector
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
JP6018069B2 (en) 2010-10-12 2016-11-02 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Methods and compositions for treating hemophilia B
JP5704361B2 (en) * 2010-10-27 2015-04-22 学校法人自治医科大学 Adeno-associated virus virion for gene transfer into nervous system cells
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
WO2012064920A1 (en) 2010-11-11 2012-05-18 University Of Miami Methods, compositions, cells, and kits for treating ischemic injury
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
WO2012109570A1 (en) * 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CN103502458B (en) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 For changing tissue specificity and improving compositions and the method for the gene transfer that AAV9-mediates
GB201103062D0 (en) 2011-02-22 2011-04-06 Isis Innovation Method
CN103492574B (en) * 2011-02-22 2015-12-09 加州理工学院 Use adeno-associated virus (AAV) vehicle delivery albumen
US20120220648A1 (en) * 2011-02-24 2012-08-30 National Taiwan University Hospital Method of Treating Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using Adeno-Associated Virus (AAV)-AADC Vector
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
WO2012144446A1 (en) 2011-04-18 2012-10-26 独立行政法人国立精神・神経医療研究センター Drug delivery particles and method for producing same
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
EP3318635A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
KR102121355B1 (en) 2011-04-22 2020-06-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Adeno-associated virus virions with variant capsid and methods of use thereof
US9249425B2 (en) 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
WO2012159006A2 (en) 2011-05-18 2012-11-22 University Of Florida Research Foundation, Inc. Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof
US20120295960A1 (en) * 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
US9863006B2 (en) 2011-06-06 2018-01-09 Biocartis Nv Selective lysis of cells by ionic surfactants
JP6122430B2 (en) 2011-07-27 2017-04-26 ジェネトン Improved baculovirus expression system
CN103857790B (en) 2011-09-08 2017-09-08 尤尼克尔Ip股份有限公司 Virus Pollution is removed from AAV preparations
WO2013036889A1 (en) 2011-09-09 2013-03-14 University Of Washington Retrograde transport peptide and use of same for delivery to central nervous system
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
ES2609860T3 (en) 2011-10-28 2017-04-24 The University Of North Carolina At Chapel Hill Cell line for the production of adeno-associated virus
WO2013078400A1 (en) 2011-11-22 2013-05-30 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
PT2814513T (en) 2012-02-14 2018-03-02 Univ California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
BR112014020325A2 (en) 2012-02-17 2017-08-08 Childrens Hospital Philadelphia aav vector compositions and methods for gene transfer to cells, organs and tissues
BR122021020419B1 (en) 2012-04-18 2023-01-17 The Children's Hospital Of Philadelphia ADENO-ASSOCIATED VIRUS (AAV) VECTOR COMPRISING A VP1 CAPSID PROTEIN, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF
US20140162319A2 (en) 2012-05-02 2014-06-12 Sangeetha Hareendran Nucleotide sequences, methods, kit and a recombinant cell thereof
US9163259B2 (en) 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
EP2847199B1 (en) 2012-05-08 2017-10-25 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI775096B (en) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
MX358019B (en) 2012-05-18 2018-08-02 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof.
CN104619832B (en) 2012-07-06 2021-03-16 衣阿华大学研究基金会 Modified adeno-associated virus vector compositions
EP2871239B1 (en) 2012-07-06 2018-08-29 Takara Bio Inc. Cell capable of producing adeno-associated virus vector
CA2880653C (en) 2012-08-01 2022-05-17 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
US10166299B2 (en) 2012-08-31 2019-01-01 The United States Of America As Represented By The Secretary Dept. Of Health And Human Services National Institutes Of Health AAV mediated aquaporin gene transfer to treat Sjogren's syndrome
CN111621507A (en) 2012-09-28 2020-09-04 北卡罗来纳-查佩尔山大学 AAV vectors targeting oligodendrocytes
WO2014071042A1 (en) 2012-10-31 2014-05-08 The Trustees Of Columbia University In The City Of New York Methods for identifying candidates for the treatment of neurodegenerative diseases
IL293526A (en) 2012-12-12 2022-08-01 Harvard College C delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN104937100B (en) 2012-12-25 2020-04-03 宝生物工程株式会社 AAV variants
DK2943567T3 (en) 2013-01-08 2018-01-02 Genzyme Corp USE OF INOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
DK2954051T3 (en) 2013-02-08 2019-07-08 Univ Pennsylvania MODIFIED KAPSID FOR TRANSFER FOR TREATMENT OF THE NETWORK
AU2014244167A1 (en) 2013-03-13 2015-10-08 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
EP3517612A1 (en) 2013-03-15 2019-07-31 The University of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
CA2904156C (en) 2013-03-15 2023-01-10 The Children's Hospital Of Philadelphia Vectors comprising stuffer/filler polynucleotide sequences and methods of use
JP6516725B2 (en) 2013-04-08 2019-05-22 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン Chimeric Adeno-Associated Virus / Bocavirus Parvovirus Vector
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
CN105408352B (en) 2013-04-18 2020-01-14 泰莱托恩基金会 Efficient delivery of large genes by dual AAV vectors
EP3461838A1 (en) 2013-04-20 2019-04-03 Research Institute at Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
JP2016523835A (en) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Adeno-associated virus-mediated gene transfer into the central nervous system
WO2014186746A1 (en) 2013-05-16 2014-11-20 University Of Florida Research Foundation, Inc. HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
JP6600624B2 (en) 2013-05-31 2019-10-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Adeno-associated virus mutant and method of use thereof
WO2014201308A1 (en) 2013-06-12 2014-12-18 Washington University Endothelial-targeted adenoviral vectors, methods and uses therefor
EP3008191A2 (en) 2013-06-13 2016-04-20 Shire Human Genetic Therapies, Inc. Messenger rna based viral production
US9840719B2 (en) 2013-07-22 2017-12-12 The Children's Hospital Of Philadelphia Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues
ES2859605T3 (en) 2013-07-26 2021-10-04 Univ Iowa Res Found Procedures and compositions for treating diseases of the brain
ITTO20130669A1 (en) 2013-08-05 2015-02-06 Consiglio Nazionale Ricerche ADENO-ASSOCIATED MOMCULAR-SPECIFIC VECTOR AND ITS EMPLOYMENT IN THE TREATMENT OF MUSCLE PATHOLOGIES
WO2015031686A1 (en) 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
PT3044231T (en) 2013-09-12 2020-08-27 Biomarin Pharm Inc Adeno-associated virus factor viii vectors
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
EP3068889B1 (en) 2013-09-26 2019-04-17 Universitat Autònoma De Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
WO2015048534A1 (en) 2013-09-26 2015-04-02 University Of Florida Research Foundation, Inc. Synthetic combinatorial aav capsid library for targeted gene therapy
EP3744730A1 (en) 2013-10-11 2020-12-02 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
WO2015060722A1 (en) 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
WO2015108610A1 (en) 2013-11-08 2015-07-23 The Board Of Trustees Of The University Of Arkansas Adeno-associated virus "x" oncogene
US9644216B2 (en) 2013-11-26 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adeno-associated virus vectors for treatment of glycogen storage disease
EP3075849B1 (en) 2013-11-29 2019-03-13 Takara Bio Inc. Method for quantifying adeno-associated virus
EP3572513A1 (en) 2013-12-09 2019-11-27 Baylor College of Medicine Hippo and dystrophin complex signaling in cardiomyocyte renewal
WO2015089351A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2015104403A1 (en) 2014-01-09 2015-07-16 Genethon Methods for diagnosing or monitoring muscular dystrophies
WO2015106273A2 (en) 2014-01-13 2015-07-16 Trustees Of Boston University Methods and assays relating to huntingtons disease and parkinson's disease
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
AU2015220920B2 (en) 2014-02-19 2019-09-12 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
WO2015124546A1 (en) 2014-02-19 2015-08-27 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic Aav vectors for the treatment of ischemic and non-ischemic heart disease
WO2015126972A1 (en) 2014-02-21 2015-08-27 University Of Florida Research Foundation, Inc. Methods and compositions for gene delivery to on bipolar cells
JP6870988B2 (en) 2014-02-24 2021-05-19 セルジーン コーポレイション How to use cereblon activators for neuronal amplification and treatment of central nervous system disorders
WO2015131076A1 (en) 2014-02-27 2015-09-03 Yale University Nlrp6 inflammasome intestinal epithelium mucus secretion
WO2015134643A1 (en) 2014-03-04 2015-09-11 University Of Florida Research Foundation, Inc. Improved raav vectors and methods for transduction of photoreceptors and rpe cells
AU2015226911B2 (en) 2014-03-07 2018-03-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
HUE051311T2 (en) 2014-03-09 2021-03-01 Univ Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
MX2016011585A (en) 2014-03-10 2016-11-29 Uniqure Ip Bv Further improved aav vectors produced in insect cells.
US20170114346A1 (en) 2014-04-03 2017-04-27 Braingene Ab Gene expression system and regulation thereof
EP3129485B2 (en) 2014-04-09 2022-12-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
EP2933335A1 (en) 2014-04-18 2015-10-21 Genethon A method of treating peripheral neuropathies and motor neuron diseases
CA2946392A1 (en) 2014-04-25 2015-10-29 James M. Wilson Ldlr variants and their use in compositions for reducing cholesterol levels
EP3134522B1 (en) 2014-04-25 2021-10-06 University of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
EP3142706A1 (en) 2014-05-16 2017-03-22 Vrije Universiteit Brussel Genetic correction of myotonic dystrophy type 1
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
EP3154560B1 (en) 2014-06-13 2019-03-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing viral vector infectivity
WO2015196179A1 (en) 2014-06-20 2015-12-23 University Of Florida Research Foundation, Inc. Methods of packaging multiple adeno-associated virus vectors
EP2960336A1 (en) 2014-06-27 2015-12-30 Genethon Efficient systemic treatment of dystrophic muscle pathologies
WO2016004319A1 (en) 2014-07-02 2016-01-07 University Of Florida Research Foundation, Inc. Compositions and methods for purifying recombinant adeno-associated virus
WO2016006658A1 (en) 2014-07-10 2016-01-14 タカラバイオ株式会社 Production method for non-enveloped virus particles
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
US10392622B2 (en) 2014-08-01 2019-08-27 The Trustees Of The University Of Pennsylvania Compositions and methods for self-regulated inducible gene expression
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
JP6842410B2 (en) 2014-10-03 2021-03-17 ユニバーシティ オブ マサチューセッツ AAV vector identified by a novel high efficiency library
WO2016057975A2 (en) 2014-10-10 2016-04-14 Research Institute At Nationwide Children's Hospital Guided injections for aav gene transfer to muscle
CN107073051B (en) 2014-10-21 2021-08-24 马萨诸塞大学 Recombinant AAV variants and uses thereof
EP3215602B1 (en) 2014-11-05 2019-12-25 The Research Institute at Nationwide Children's Hospital Methods and materials for producing recombinant viruses in eukaryotic microalgae
KR20170096998A (en) 2014-11-05 2017-08-25 보이저 테라퓨틱스, 인크. Aadc polynucleotides for the treatment of parkinson's disease
BR112017010498A2 (en) 2014-11-19 2017-12-26 Axon Neuroscience Se humanized tau antibodies in alzheimer's disease
EP3221456B1 (en) 2014-11-21 2021-09-22 University of Florida Research Foundation, Inc. Genome-modified recombinant adeno-associated virus vectors
RU2727015C2 (en) 2014-11-21 2020-07-17 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Aav vectors aimed at the central nervous system
CN107208142B (en) 2014-11-28 2024-03-26 优尼科Ip有限公司 DNA impurities in compositions comprising parvoviral virions
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
EP3250279B1 (en) 2015-01-30 2020-08-19 The Regents of the University of California Spinal subpial gene delivery system
WO2016126857A1 (en) 2015-02-03 2016-08-11 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
CR20170407A (en) 2015-02-10 2017-11-14 Genzyme Corp IMPROVEMENT OF SUPPLY OF VIRAL PARTICLES TO THE CORRECTED BODY AND THE CORTEX
EP3262162A4 (en) 2015-02-23 2018-08-08 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
DK3268024T3 (en) 2015-03-10 2020-12-07 Univ Columbia RECOMBINANT GLUT1 ADENO ASSOCIATED VIRUS VECTOR CONSTRUCTIONS AND RELATED METHODS FOR RECOVERING GLUT1 EXPRESSION
EP3270960A4 (en) 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
MX2017012097A (en) 2015-03-24 2018-06-15 Univ California Adeno-associated virus variants and methods of use thereof.
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
US10081659B2 (en) 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
TWI707951B (en) 2015-04-08 2020-10-21 美商健臻公司 Production of oversized adeno-associated vectors
EP3626274A3 (en) 2015-04-16 2020-06-17 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
US11020443B2 (en) 2015-04-23 2021-06-01 University Of Massachusetts Modulation of AAV vector transgene expression
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
US20160346359A1 (en) 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
EP3291765A4 (en) 2015-05-07 2019-01-23 Massachusetts Eye & Ear Infirmary Methods of delivering an agent to the eye
WO2016183123A1 (en) 2015-05-11 2016-11-17 Alcyone Lifesciences, Inc. Drug delivery systems and methods
JP6805174B2 (en) 2015-05-12 2020-12-23 アメリカ合衆国 AAV isolates and fusion proteins containing nerve growth factor signal peptides and parathyroid hormone
US20170067028A1 (en) 2015-05-15 2017-03-09 Douglas J. Ballon Radiolabeling of adeno associated virus
WO2016191418A1 (en) 2015-05-26 2016-12-01 Salk Institute For Biological Studies Motor neuron-specific expression vectors
CA2987103A1 (en) 2015-05-28 2016-12-01 Cornell University Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
WO2016196328A1 (en) 2015-05-29 2016-12-08 The Trustees Of The University Of Pennsylvania Compositions and methods for degradation of misfolded proteins
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
US10799566B2 (en) 2015-06-23 2020-10-13 The Children's Hospital Of Philadelphia Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues
US11266748B2 (en) 2015-07-02 2022-03-08 University Of Florida Research Foundation, Incorporated Recombinant adeno-associated virus vectors to target medullary thyroid carcinoma
WO2017005806A1 (en) 2015-07-07 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject
US20170007669A1 (en) 2015-07-07 2017-01-12 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of active agents across the blood-brain barrier
WO2017015102A1 (en) 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Compositions and methods for achieving high levels of transduction in human liver cells
WO2017019876A1 (en) 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
LT3872085T (en) 2015-07-30 2023-05-10 Massachusetts Eye & Ear Infirmary Ancestral aav sequences and uses thereof
WO2017023724A1 (en) 2015-07-31 2017-02-09 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
WO2017024198A1 (en) 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
CA2999297A1 (en) 2015-09-24 2017-03-30 Biomarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
JP7064214B2 (en) 2015-09-28 2022-05-10 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and Compositions for Antibodies Avoidant Viral Vectors
CN108368504B (en) 2015-10-09 2022-07-19 建新公司 Early post-transfection isolation (EPIC) of cells for bioproduct production
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
CA3002980A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
EP3364997B1 (en) 2015-10-22 2024-01-17 University of Massachusetts Aspartoacylase gene therapy in the treatment of canavan disease
US20200181644A1 (en) 2015-10-22 2020-06-11 University Of Florida Research Foundation, Incorporated Synthetic combinatorial aav3 capsid library
AU2016341428B2 (en) 2015-10-23 2021-12-02 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
KR20180100304A (en) 2015-10-28 2018-09-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Intra-spinal administration of adeno-associated-viral vectors for gene therapy
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
JP6998869B2 (en) 2015-11-08 2022-02-04 ジェネンテック， インコーポレイテッド Screening method for multispecific antibody
WO2017083423A1 (en) 2015-11-10 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating aav infection
US20170151416A1 (en) 2015-12-01 2017-06-01 Invivo Therapeutics Corporation Methods and Systems for Delivery of a Trail of a Therapeutic Substance into an Anatomical Space
CA3006309A1 (en) 2015-12-01 2017-06-08 Spark Therapeutics, Inc. Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
US10406244B2 (en) 2015-12-02 2019-09-10 The Board Of Trustees Of The Leland Stanford Junior University AAV vectors with expanded packaging capacity
US10385320B2 (en) 2015-12-02 2019-08-20 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
EP3383896A1 (en) 2015-12-03 2018-10-10 Genethon Compositions and methods for improving viral vector efficiency
SG11201804713VA (en) 2015-12-11 2018-07-30 California Inst Of Techn TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
ES2918998T3 (en) 2015-12-11 2022-07-21 Univ Pennsylvania Scalable purification method for AAVrh10
US11098286B2 (en) 2015-12-11 2021-08-24 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV9
US11015174B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
MX2018007237A (en) 2015-12-14 2018-12-11 Univ North Carolina Chapel Hill Modified capsid proteins for enhanced delivery of parvovirus vectors.
WO2017112948A1 (en) 2015-12-24 2017-06-29 University Of Florida Research Foundation, Inc. Improved aav production using suspension adapted cells
EP3402530B1 (en) 2016-01-13 2020-08-19 Genzyme Corporation Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
ES2871527T3 (en) 2016-01-15 2021-10-29 Univ Jichi Medical Adeno-associated virus virion for use in the treatment of epilepsy
CA3011939A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
HRP20231451T1 (en) 2016-02-05 2024-03-01 Emory University Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CN109415704B (en) 2016-02-16 2022-02-25 利兰斯坦福初级大学董事会 Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
WO2017147477A1 (en) 2016-02-26 2017-08-31 University Of Florida Research Foundation, Inc. Aav heparin mutants that display significantly improved eye and brain transduction
EP3423109A4 (en) 2016-03-02 2019-08-14 The Children's Hospital of Philadelphia Therapy for frontotemporal dementia
SG11201806663TA (en) 2016-03-03 2018-09-27 Univ Massachusetts Closed-ended linear duplex dna for non-viral gene transfer
AU2017229347A1 (en) 2016-03-07 2018-11-01 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
WO2017165167A1 (en) 2016-03-23 2017-09-28 The Regents Of The University Of California Methods of treating mitochondrial disorders
WO2017165859A1 (en) 2016-03-24 2017-09-28 Research Institute At Nationwide Children's Hospital Modified viral capsid proteins
WO2017172733A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
US11013774B2 (en) 2016-03-28 2021-05-25 Ultragenyx Pharmaceutical Inc. Methods of heat inactivation of adenovirus
CA3019126A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
MY195391A (en) 2016-03-31 2023-01-18 Spark Therapeutics Inc Column-Based Fully Scalable Raav Manufacturing Process
JP7140683B2 (en) 2016-04-15 2022-09-21 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Novel AAV8 Mutant Capsids and Compositions Containing Them
CN109311932B (en) 2016-04-16 2022-05-03 佛罗里达大学研究基金会有限公司 Method for improving biological effectiveness of recombinant adeno-associated virus produced by baculovirus system
WO2017184879A1 (en) 2016-04-21 2017-10-26 Virovek, Inc Aav production in insect cells, methods and compositions therefor
EP3235516B1 (en) 2016-04-22 2019-06-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Regulatable adeno-associated virus (aav) vector
EP3449250B1 (en) 2016-04-28 2020-11-04 Indiana University Research & Technology Corporation Methods and compositions for resolving components of a virus preparation
US10882886B2 (en) 2016-05-03 2021-01-05 Children's Medical Research Institute Adeno-associated virus polynucleotides, polypeptides and virions
US11866462B2 (en) 2016-05-04 2024-01-09 Oregon Health & Science University Recombinant adeno-associated viral vectors
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
US20210198691A1 (en) 2018-05-15 2021-07-01 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease

Also Published As

Publication number Publication date
US20190008932A1 (en) 2019-01-10
US20210338786A1 (en) 2021-11-04
US20190008933A1 (en) 2019-01-10
JP2017535291A (en) 2017-11-30
US20190008931A1 (en) 2019-01-10
RU2017115477A3 (en) 2019-03-26
EP3215191A4 (en) 2018-08-01
CA2966620A1 (en) 2016-05-12
AU2015343037A1 (en) 2017-05-11
US11027000B2 (en) 2021-06-08
WO2016073693A2 (en) 2016-05-12
RU2020109343A (en) 2020-03-17
US20170333538A1 (en) 2017-11-23
AU2019202498B2 (en) 2021-04-01
EP3215191A2 (en) 2017-09-13
JP2021106619A (en) 2021-07-29
CN107106689A (en) 2017-08-29
IL251787B (en) 2021-02-28
US20190358306A1 (en) 2019-11-28
IL280530A (en) 2021-03-01
BR112017009497A2 (en) 2018-02-06
MX2017005834A (en) 2017-11-17
RU2017115477A (en) 2018-11-09
KR20170096998A (en) 2017-08-25
HK1243922A1 (en) 2018-07-27
RU2716991C2 (en) 2020-03-17
JP2019010110A (en) 2019-01-24
JP6401871B2 (en) 2018-10-10
WO2016073693A3 (en) 2016-06-30
JP2018198622A (en) 2018-12-20
SG11201703148TA (en) 2017-05-30
JP6878370B2 (en) 2021-05-26
US11975056B2 (en) 2024-05-07
IL251787A0 (en) 2017-06-29
AU2019202498A1 (en) 2019-05-02
US10335466B2 (en) 2019-07-02
CN112553229A (en) 2021-03-26
AU2015343037B2 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
IL280530A (en) Aadc polynucleotides for the treatment of parkinson's disease
IL270821A (en) Aadc polynucleotides for the treatment of parkinson’s disease
IL285722A (en) Methods for treating alzheimer's disease
PL2968218T3 (en) Combination for the treatment of parkinson's disease
ZA201605341B (en) Methods of treating alzheimer's disease
IL247085A0 (en) Methods of treating alzheimer's disease
IL263188B (en) Treatment for parkinson's disease
IL248592A0 (en) Treatment of crohn's disease with delayed-release 6-mercaptopurine
EP3538095A4 (en) Methods for treating parkinson's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
HK1244449A1 (en) Methods for treating psychosis associated with parkinson's disease
HK1245081A1 (en) Methods for treating alzheimer's disease
GB201504144D0 (en) Treatment of Parkinson's disease
GB201610205D0 (en) Therapies for parkinson's disease
GB201602011D0 (en) Treating skin disorders
GB201414038D0 (en) Alzheimer's disease
GB201406225D0 (en) Treatment for respiratory disease